Floatz logo

Topamax

Hyperlipidemia

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Hyperlipidemia cohort.

Asset / SponsorPhaseRating
Lipitor
Poznan University of Medical Sciences
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
PRAVASTATIN
University of North Carolina, Chapel Hill
Phase 4BBB
Ezetimibe
NewAmsterdam Pharma
Phase 4BBB
Darunavir
University of Colorado, Denver
Phase 4BB

View all 36 →

Same molecule, other indications

Topamax is also rated in:

focal epilepsyDormant
A
Indicative ·
80 / 100
View asset →
migraine without auraDormant
BBB
Indicative ·
78 / 100
View asset →
migraine with auraDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →